Cardiosense Appoints Eric Meizlish as CEO to Advance AI-Enabled Cardiac Care
Cardiosense, a digital health company pioneering AI-enabled solutions for cardiac disease management, today announced the appointment of Eric Meizlish as Chief Executive Officer (CEO). Meizlish, a seasoned healthcare technology executive with experience scaling innovative health platforms, will lead the company through its next phase of growth, succeeding co-founder Amit Gupta, who will continue as Chief Strategy Officer.
Cardiosense Appoints Medtech Executive John Martin, MD as EVP and Chief Medical Officer
Cardiosense, a leading medical AI company transforming cardiovascular disease management, today announced the appointment of John Martin, MD, MBA, as Executive Vice President and Chief Medical Officer. Martin, a practicing vascular surgeon and seasoned healthtech executive, will lead the company’s clinical development and product strategy as the company advances through key regulatory milestones and prepares for commercial launch.
Cardiosense Receives FDA 510(k) Clearance for the CardioTag™ Device, Paving the Way for Advanced Cardiac Function Monitoring
Cardiosense, a medical AI company transforming cardiovascular disease management, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the CardioTag device, the first multimodal, wearable sensor that simultaneously captures high-fidelity electrocardiogram (ECG), photoplethysmogram (PPG), and seismocardiogram (SCG) signals, empowering clinicians and patients with a comprehensive noninvasive solution to assess cardiac function across care settings.
Cardiosense Announces Publication of SEISMIC-HF I Study Results in the Journal of the American College of Cardiology: Heart Failure
Cardiosense, a medical AI company transforming the management of cardiovascular disease, today announced the publication of results from its SEISMIC-HF I study in the Journal of the American College of Cardiology: Heart Failure (JACC: Heart Failure). The study demonstrates the ability of Cardiosense's novel machine learning (ML) algorithm to noninvasively estimate pulmonary capillary wedge pressure (PCWP) in patients with heart failure with reduced ejection fraction (HFrEF).
Cardiosense Launches Nationwide SEISMIC-HF II Study to Validate Its AI Algorithm for Non-Invasive Heart Failure Management
Cardiosense, a medical AI company transforming cardiovascular disease management, today announced the launch of SEISMIC-HF II, a nationwide study to validate the company’s machine learning algorithm for assessing intracardiac filling pressure, an early indicator of acute heart failure decompensation. This milestone marks a critical step forward in advancing Cardiosense’s mission to enable access to smarter, personalized cardiac care for all heart failure patients.
